Editorial on Screening for Lung Cancer by Sateia et al
In their review article, Satiea et al. discuss the burden of lung cancer and the potential benefits and harms of low-dose CT (LDCT) lung cancer screening [1]. As lung cancer is the most common cause of cancer mortality in the developing world, the promise of a mortality reduction on the order of 15-20% among those undergoing screening, as observed in the National Lung Screening Trial (NLST), is alluring. However, for the potential of LDCT screening to be optimized, the harms must be minimized and screening must be effectively targeted to persons both at high risk and also able to benefit from curative treatments. (Source: ...
Source: Seminars in Oncology - February 7, 2017 Category: Cancer & Oncology Authors: Paul F. Pinsky Source Type: research
Editorial to Accompany Peairs et al
This issue of Seminars in Oncology includes a review article by Peairs et al entitled “Screening for breast cancer”. As expected, the primary focus of the article is breast cancer screening; the authors report on the harms and benefits of screening, use of different modalities and screening intervals, professional guidelines, and screening in high-risk groups. The review article places this in the context of providing personalized recommendations for a 48-year-old African American woman. The authors provide a detailed discussion on breast cancer risk factors relevant to the final part of the article, which covers the a...
Source: Seminars in Oncology - February 7, 2017 Category: Cancer & Oncology Authors: Pamela M. Marcus, Danielle D. Durham Source Type: research
outside front cover
(Source: Seminars in Oncology)
Source: Seminars in Oncology - February 1, 2017 Category: Cancer & Oncology Source Type: research
Masthead
(Source: Seminars in Oncology)
Source: Seminars in Oncology - February 1, 2017 Category: Cancer & Oncology Source Type: research
Editorial Board
(Source: Seminars in Oncology)
Source: Seminars in Oncology - February 1, 2017 Category: Cancer & Oncology Source Type: research
Table of Contents
(Source: Seminars in Oncology)
Source: Seminars in Oncology - February 1, 2017 Category: Cancer & Oncology Source Type: research
WITHDRAWN: Recommend Maintenance Therapy with Lenalidomide
The Publisher regrets that this article is an accidental duplication of an article that has already been published, DOI of original article: 10.1053/j.seminoncol.2016.11.002. The duplicate article has therefore been withdrawn.The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy. (Source: Seminars in Oncology)
Source: Seminars in Oncology - December 2, 2016 Category: Cancer & Oncology Authors: Elisabet E Manasanch Source Type: research
WITHDRAWN: Treatment of Newly Diagnosed Myeloma: Bortezomib-based Triplet
The Publisher regrets that this article is an accidental duplication of an article that has already been published, DOI of original article10.1053/j.seminoncol.2016.11.003. The duplicate article has therefore been withdrawn.The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy. (Source: Seminars in Oncology)
Source: Seminars in Oncology - December 2, 2016 Category: Cancer & Oncology Authors: Archana M. Rajan, S. Vincent Rajkumar Source Type: research
Recommend Maintenance Therapy with Lenalidomide
Thalidomide was the first immunomodulatory drug used as maintenance after autologous stem cell transplant (autoSCT) in myeloma. This showed improved progression-free survival (PFS) and in some cases, overall survival (OS) [1 –3]. Despite this, use of thalidomide was limited due to toxicity and high rates of therapy discontinuation. Lenalidomide, an analog of thalidomide, had a more favorable toxicity profile making its use in maintenance a potential approach. The use of lenalidomide as a maintenance therapy after auto logous stem cell transplant in newly diagnosed multiple myeloma patients was then investigated in four p...
Source: Seminars in Oncology - December 2, 2016 Category: Cancer & Oncology Authors: Elisabet E Manasanch Tags: Mailankody: Myeloma Source Type: research
Treatment of Newly Diagnosed Myeloma: Bortezomib-based Triplet
In this paper we review the options for the treatment of newly diagnosed myeloma in a patient who is a candidate for autologous stem cell transplantation. Bortezomib, lenalidomide, dexamethasone (VRD) has been studied in two randomized trials as first line therapy. In one of these trials, VRD demonstrated improved overall survival compared with lenalidomide plus dexamethasone (Rd). By contrast, phase III data with overall survival differences are not available for other bortezomib containing regimens compared with modern lenalidomide containing regimens. (Source: Seminars in Oncology)
Source: Seminars in Oncology - December 2, 2016 Category: Cancer & Oncology Authors: Archana M. Rajan, S. Vincent Rajkumar Source Type: research
outside front cover
(Source: Seminars in Oncology)
Source: Seminars in Oncology - November 30, 2016 Category: Cancer & Oncology Source Type: research
Masthead
(Source: Seminars in Oncology)
Source: Seminars in Oncology - November 30, 2016 Category: Cancer & Oncology Source Type: research
Editorial Board
(Source: Seminars in Oncology)
Source: Seminars in Oncology - November 30, 2016 Category: Cancer & Oncology Source Type: research
Table of Contents
(Source: Seminars in Oncology)
Source: Seminars in Oncology - November 30, 2016 Category: Cancer & Oncology Source Type: research
The use of novel oral anticoagulants in cancer patients with venous thromboembolism
Venous thromboembolism (VTE) is not uncommon among patients with cancer and is one of the major causes of mortality and morbidity. Treatment with low-molecular-weight heparin (LMWH) is effective, yet accompanied by the need for daily administration of injections for a prolonged time and (even rarely) thrombocytopenia. The discovery of novel oral anticoagulants (NOACs) was based on an effort to improve the pharmacodynamic and pharmacokinetic properties of previous generation anticoagulants while maintaining efficacy without the need for daily subcutaneous administration and frequent laboratory monitoring. (Source: Seminars in Oncology)
Source: Seminars in Oncology - November 17, 2016 Category: Cancer & Oncology Authors: Stamatis J. Karakatsanis, Aikaterini Roumpi, Konstantinos N. Syrigos Source Type: research
